Jones G R, Lazarus J H, Wynford-Thomas D
Br J Clin Pharmacol. 1981 Dec;12(6):825-8. doi: 10.1111/j.1365-2125.1981.tb01314.x.
1 The effects of propranolol in its long acting formulation, 160 mg long acting (LA) propranolol, were assessed in a double-blind, controlled study of 20 hyperthyroid patients. Further observations with the addition of carbimazole were also made. 2 LA propranolol effectively improved the clinical manifestations of hyperthyroidism. 3 Plasma concentrations of total T4 and rT3 were increased, but total T3 did not fall significantly during LA propranolol treatment. 4 LA propranolol with carbimazole produced a greater reduction in the clinical indices of hyperthyroidism than carbimazole alone. 5 Total serum T4 and rT3 concentrations remained elevated with LA propranolol and carbimazole compared to carbimazole alone. 6 Carbimazole therapy for 2 weeks did not alter the mean plasma propranolol concentration. 7 We concluded that LA propranolol is effective in hyperthyroidism and its effects are similar to those reported by other workers with conventional propranolol. The clinical and biochemical effects of LA propranolol continue during concomitant carbimazole therapy.
在一项对20名甲状腺功能亢进患者进行的双盲对照研究中，评估了长效普萘洛尔（160毫克长效普萘洛尔）的效果。还进行了添加卡比马唑后的进一步观察。
长效普萘洛尔有效改善了甲状腺功能亢进的临床表现。
在长效普萘洛尔治疗期间，总T4和反T3的血浆浓度升高，但总T3没有显著下降。
与单独使用卡比马唑相比，长效普萘洛尔联合卡比马唑能使甲状腺功能亢进的临床指标有更大程度的降低。
与单独使用卡比马唑相比，长效普萘洛尔联合卡比马唑治疗时，血清总T4和反T3浓度仍保持升高。
卡比马唑治疗2周未改变血浆普萘洛尔的平均浓度。
我们得出结论，长效普萘洛尔对甲状腺功能亢进有效，其效果与其他研究人员使用传统普萘洛尔所报告的效果相似。在联合使用卡比马唑治疗期间，长效普萘洛尔的临床和生化作用持续存在。
